About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AGEN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 5, 2026A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044 · Metastatic Colorectal Cancer
Botensilimab, Balstilimab
AGEN
Agenus Inc.
Phase 2Active, not recruiting234Sep 2027Registry ↗
Nov 4, 2026Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
NCT05572970 · Cancer
Balstilimab, Zalifrelimab
AGEN
Agenus Inc.
—Available——Registry ↗
Oct 19, 2026A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316 · Advanced Melanoma
Botensilimab, Balstilimab
AGEN
Agenus Inc.
Phase 2Terminated150Apr 27, 2026Registry ↗
Aug 11, 2026A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Ad…
NCT03495882 · Cervical Cancer
Zalifrelimab, Balstilimab
AGEN
Agenus Inc.
Phase 1/2Completed175Jul 15, 2022Registry ↗
Jun 11, 2026A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183 · Metastatic Pancreatic Ductal Adenocarcinoma
Botensilimab, Gemcitabine
AGEN
Agenus Inc.
Phase 2Completed81Jan 5, 2026Registry ↗
May 15, 2026Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Reg…
NCT06751524 · Colorectal Cancer (CRC), Pancreatic Cancer
Botensilimab, Balstililmab
AGEN
Agenus Inc.
—Available——Registry ↗
Mar 30, 2026Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272 · Advanced Cancer, Angiosarcoma
Botensilimab, Balstilimab
AGEN
Agenus Inc.
Phase 1Active, not recruiting499Jan 13, 2025Registry ↗
Mar 27, 2026RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Lin…
NCT03894215 · Cervical Cancer
AGEN2034, AGEN1884
AGEN
Agenus Inc.
Phase 2Terminated211Mar 26, 2025Registry ↗
Oct 15, 2025A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
NCT05025085 · Advanced Cancer
AGEN1777, a PD-1 inhibitor
AGEN
Agenus Inc.
Phase 1Completed25Jul 11, 2023Registry ↗
Jul 30, 2025A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
NCT03104699 · Advanced Cancer, Cervical Cancer
AGEN2034
AGEN
Agenus Inc.
Phase 1/2Completed211Jun 15, 2022Registry ↗
Apr 30, 2025Study of AGEN1571 in Participants With Advanced Solid Tumors
NCT05377528 · Advanced Solid Tumor
AGEN1571, Balstilimab
AGEN
Agenus Inc.
Phase 1Completed22Dec 23, 2024Registry ↗
Mar 17, 2025AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Canc…
NCT02694822 · Advanced Solid Cancers, Advanced Solid Cancers Refractory t…
Zalifrelimab
AGEN
Agenus Inc.
Phase 1/2Completed89Mar 30, 2022Registry ↗
Jan 13, 2025Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
NCT04121676 · Advanced Cancer
AGEN2373, Botensilimab
AGEN
Agenus Inc.
Phase 1Completed91Feb 22, 2024Registry ↗
Mar 28, 2024A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervi…
NCT05033132 · Cervical Cancer
Balstilimab, Balstilimab + Zalifrelimab
AGEN
Agenus Inc.
Phase 2Withdrawn0Dec 30, 2024Registry ↗
Sep 28, 2023A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
NCT00081809 · Lymphoma, Follicular, Lymphoma, Small Lymphocytic
autologous human tumor-derived HSPPC-96
AGEN
Agenus Inc.
Phase 2Completed35Jun 2005Registry ↗
Oct 5, 2022Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRA…
NCT04943627 · Advanced Cancer, Metastatic Cervical Cancer
Balstilimab (BAL), Topotecan
AGEN
Agenus Inc.
Phase 3Withdrawn0Oct 22, 2021Registry ↗
Mar 3, 2022A Study in Subjects With Advanced Solid Tumors
NCT04156100 · Advanced Solid Tumor
AGEN1223, AGEN1223 and balstilimab
AGEN
Agenus Inc.
Phase 1Terminated19Apr 8, 2021Registry ↗
Jan 11, 2022AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
NCT04607200 · Angiosarcoma
AGEN2034, AGEN1884
AGEN
Agenus Inc.
Phase 2Withdrawn0Sep 13, 2021Registry ↗
Dec 2, 2021Phase 1a Study to Evaluate Immunogenicity of ASV®
NCT03673020 · Solid Tumor, Adult
ASV® AGEN2017 + QS-21 Stimulon® adjuvant
AGEN
Agenus Inc.
Phase 1Completed3Feb 3, 2021Registry ↗
Jul 13, 2021Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital…
NCT01687595 · Herpes Simplex Type 2
HerpV and QS-21, Placebo
AGEN
Agenus Inc.
Phase 2Completed80Sep 2013Registry ↗
Jun 3, 2021Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resec…
NCT01147536 · Renal Cell Carcinoma
HSPPC-96
AGEN
Agenus Inc.
Phase 2Terminated12Jun 2012Registry ↗
Jun 2, 2020Study of AGEN1884 With Pembrolizumab in 1L NSCLC
NCT03411473 · NSCLC Stage IV
AGEN1884 in combination with pembrolizumab
AGEN
Agenus Inc.
Phase 2Terminated2May 1, 2018Registry ↗
Jun 2, 2020Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
NCT02992977 · Advanced Cancer
AutoSynVax™ vaccine
AGEN
Agenus Inc.
Phase 1Terminated3Dec 2018Registry ↗

23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:40 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances